JSPR, US4718712023

Jasper Therapeutics stock fell 5.52 percent as Q2 loss narrowed

Published on 10/07/2026 at 03:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Jasper Therapeutics posted a USD 2.76 million Q2 loss on August 14, 2026, down from USD 26.72 million. Zacks tracks five price-target reports averaging USD 6.50.

JSPR, US4718712023, Illustration mit AI erstellt.

Jasper Therapeutics stock (ISIN US4718712023) was last at USD 0.56 on Nasdaq on October 6, 2026, down 5.52 percent from the prior close. The move leaves the company with a market capitalization of USD 9.1 million and makes the upcoming capital structure decisions central to the stock story.

Stock stays near its yearly floor

The October 6 trading range was USD 0.55 to USD 0.60, with volume of 328,609 shares. The 52-week range is USD 0.32 to USD 2.69, putting the latest price USD 0.24 above the low and USD 2.13 below the high.

Jasper trades on Nasdaq under the ticker JSPR. Its market capitalization is small relative to the authorized share base approved by shareholders, so future share-count decisions can materially change the per-share calculation even when the company's underlying value is unchanged.

Q2 loss narrowed sharply

RTT News reported on September 16, 2026 that Jasper's second-quarter 2026 net loss was USD 2.76 million, or USD 0.10 per share, compared with a USD 26.72 million loss, or USD 1.74 per share, in the second quarter of 2025. The net loss therefore narrowed by 89.67 percent year over year.

The same report placed cash and cash equivalents at USD 7.3 million as of June 30, 2026. Jasper describes its pipeline as including KP-104, briquilimab and KP-701, with programs targeting immune-mediated diseases, according to the Jasper Therapeutics investor-relations page.

Analyst targets remain wide

Zacks lists five analyst price-target reports for Jasper, with an average target of USD 6.50, a low of USD 1.50 and a high of USD 20.00. Against the USD 0.60 last close used by Zacks, the average target represents 983.33 percent upside, while the spread between the low and high target is USD 18.50.

The governance decision adds a separate variable. As reported in the September 30, 2026 filing by StockTitan, shareholders approved a reverse split range of 1-for-15 to 1-for-35 and an increase in authorized shares from 490.0 million to 675.0 million. The board can act on the reverse split through December 31, 2026.

Nasdaq price and investor perspective

Jasper Therapeutics was last at USD 0.56 on Nasdaq on October 6, 2026. The share price, USD 7.3 million of cash at June 30 and the approved 1-for-15 to 1-for-35 range define the key variables for investors assessing dilution and clinical execution.